Abstract
Thionamide-derived antithyroid drugs (ATD) have been in use for over half a century and much is now known about their mechanism of action, pharmacokinetics and clinical pharmacology. Candidates for first option ATD therapy are young adults, without large goitre. The recommended initial dose for patients without big goitre and mild hyperthyroidism is 20 mg of MMI/CBZ. The recommended maintenance doses are 5-10 mg of MMI/CBZ. In cases of big goitre and/or severe hyperthyroidism the recommended initial dose is 30 to 40 mg/day. PTU use should be restricted to first trimester of pregnancy, doses should be as low as possible (150 to 200 mg/day) and then changing to MMI is recommended. Treatment Duration should be of 12-18 months. ATD plus thyroxine combination therapy have not advantage on ATD alone. ATD plus L-Thyroxine regimens should be used to avoid hypothyroidism when patients are with maintenance doses of ATD drugs in order to relax monitoring. In this case a low dose of T4 50-75 µg per day is used. Breast feeding women with hyperthyroidism can be treated with MMI/CBZ. ATD will not stop until serum stimulating TSH-receptors antibodies values are within the normal range. We are waiting for results of ongoing studies of biochemical and/or genetic markers that will permit us to predict the outcome of these patients after ATD treatment is stopped.
Keywords: Graves' hyperthyroidism, ATD, goitre, stimulating TSH-receptor antibodies, TSH, FT4, pregnancy, children, Thionamides-Derived Drugs, thyroxine, TSH-receptors, TSH, FT4, autoimmune disor-der, thyrotropin, antithyroid therapy, euthyroidism, thyroid hormone, tyrosine residues, thyroglobulin, Propylthiouracil, methimazole, carbimazole, interleukin-2, interleukin-6, HLA class II expres-sion, helper T cells, suppressor T cells, antihistamine, polyarthritis, antithyroid arthritis syndrome, Agranulocytosis, granulocyte colony-stimulating factor, sialadenitis, ANCA-positive vasculitis, Immunoallergic hepatitis, Cholestasis, MMI-embryopathy, L-thyroxine, ANTITHYROID TREATMENT, Thyrotoxicosis, The Endocrine Society guideline, cordocentesis, American Academy of Paediatrics, MMI/CBZ
Medicinal Chemistry
Title: Treatment of Graves Hyperthyroidism with Thionamides-Derived Drugs: Review
Volume: 6 Issue: 4
Author(s): Ricardo V. Garcia-Mayor and Alejandra Larranaga
Affiliation:
Keywords: Graves' hyperthyroidism, ATD, goitre, stimulating TSH-receptor antibodies, TSH, FT4, pregnancy, children, Thionamides-Derived Drugs, thyroxine, TSH-receptors, TSH, FT4, autoimmune disor-der, thyrotropin, antithyroid therapy, euthyroidism, thyroid hormone, tyrosine residues, thyroglobulin, Propylthiouracil, methimazole, carbimazole, interleukin-2, interleukin-6, HLA class II expres-sion, helper T cells, suppressor T cells, antihistamine, polyarthritis, antithyroid arthritis syndrome, Agranulocytosis, granulocyte colony-stimulating factor, sialadenitis, ANCA-positive vasculitis, Immunoallergic hepatitis, Cholestasis, MMI-embryopathy, L-thyroxine, ANTITHYROID TREATMENT, Thyrotoxicosis, The Endocrine Society guideline, cordocentesis, American Academy of Paediatrics, MMI/CBZ
Abstract: Thionamide-derived antithyroid drugs (ATD) have been in use for over half a century and much is now known about their mechanism of action, pharmacokinetics and clinical pharmacology. Candidates for first option ATD therapy are young adults, without large goitre. The recommended initial dose for patients without big goitre and mild hyperthyroidism is 20 mg of MMI/CBZ. The recommended maintenance doses are 5-10 mg of MMI/CBZ. In cases of big goitre and/or severe hyperthyroidism the recommended initial dose is 30 to 40 mg/day. PTU use should be restricted to first trimester of pregnancy, doses should be as low as possible (150 to 200 mg/day) and then changing to MMI is recommended. Treatment Duration should be of 12-18 months. ATD plus thyroxine combination therapy have not advantage on ATD alone. ATD plus L-Thyroxine regimens should be used to avoid hypothyroidism when patients are with maintenance doses of ATD drugs in order to relax monitoring. In this case a low dose of T4 50-75 µg per day is used. Breast feeding women with hyperthyroidism can be treated with MMI/CBZ. ATD will not stop until serum stimulating TSH-receptors antibodies values are within the normal range. We are waiting for results of ongoing studies of biochemical and/or genetic markers that will permit us to predict the outcome of these patients after ATD treatment is stopped.
Export Options
About this article
Cite this article as:
V. Garcia-Mayor Ricardo and Larranaga Alejandra, Treatment of Graves Hyperthyroidism with Thionamides-Derived Drugs: Review, Medicinal Chemistry 2010; 6 (4) . https://dx.doi.org/10.2174/1573406411006040239
DOI https://dx.doi.org/10.2174/1573406411006040239 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adenosine A<sub>3</sub> Receptor: A promising therapeutic target in cardiovascular disease
Current Cardiology Reviews Omalizumab: Not Only For Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Current Evidence and Future Perspectives on Anti-platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease
Current Vascular Pharmacology The Physiological Characteristics and Transcytosis Mechanisms of the Blood-Brain Barrier (BBB)
Current Pharmaceutical Biotechnology Mechanisms of Neurodegeration in Type 2 Diabetes and the Neuroprotective Potential of Dipeptidyl Peptidase 4 Inhibitors
Current Medicinal Chemistry Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part I
Inflammation & Allergy - Drug Targets (Discontinued) Medicinal Plants and Atherosclerosis: A Review on Molecular Aspects
Current Pharmaceutical Design Hypereosinophilic Syndrome, Churg-Strauss Syndrome and Parasitic Diseases: Possible Links between Eosinophilia and Thrombosis
Current Vascular Pharmacology A Pictorial Review of Intracranial Haemorrhage Revisited
Current Medical Imaging Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Hypersensitivity to Lamotrigine and Nonaromatic Anticonvulsant Drugs: A Review
Current Pharmaceutical Design Towards a Better Understanding of Cardiac and Vascular Disease in Patients with Chronic Kidney Disease
Current Cardiology Reviews Environmental Factors Modifying HDL Functionality
Current Medicinal Chemistry Drug Transport Across the Blood-Brain Barrier and the Impact of Breast Cancer Resistance Protein (ABCG2)
Current Topics in Medicinal Chemistry Emerging Targets in Neurodegeneration: New Opportunities for Alzheimer's Disease Treatment?
Current Topics in Medicinal Chemistry Foreword: The Year in Review: Comments on Plants, Cyclodextrins, Microbiota, and Diabetes
Current Pharmaceutical Design Anti-angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims
Current Cancer Therapy Reviews Diffuse Alveolar Hemorrhage, A Potentially Life-Threatening Manifestation in Systemic Lupus Erythematosus and the Antiphospholipid Syndrome
Current Respiratory Medicine Reviews Exercise Induced Cardioprotection: An Overview of a Unique Form of Preconditioning
Current Cardiology Reviews Modelling the Neurovascular Unit and the Blood-Brain Barrier with the Unique Function of Pericytes
Current Neurovascular Research